Clinical profile of patients with Guillain Barré Syndrome in a hospital of Santa Catarina
DOI:
https://doi.org/10.34024/rnc.2024.v32.16353Keywords:
Guillain-Barré syndrome, Neutrophils, Protein-cytological dissociation, intravenous immunoglobulinAbstract
Introduction. Guillain-Barré syndrome (GBS) can be defined as an inflammatory polyradiculoneuropathy of autoimmune origin, characterized by the onset of ascending and progressive paresis and paresthesia. Objective. To know the clinical and epidemiological profile of patients diagnosed with GBS in a hospital in the south of Santa Catarina. Method. An observational epidemiological study with a cross-sectional design was carried out using secondary data. Results. 33 medical records of patients diagnosed with GBS were analyzed, of which 57.6% were male and white (94%). It was observed that only 36.4% of patients were not discharged after two weeks, complications were found in up to 84.8% of cases, showing a close relationship with protein-cytological dissociation and with the increase in neutrophil populations. Intravenous immunoglobulin corresponds to the treatment method established for 69.7% of patients. Conclusion. The relationship between serum concentrations of neutrophils seems to express an intrinsic relationship with the evolution of the condition under study. In addition, its management with immunoglobulin represents the best-established method for controlling the evolution of sensory-motor symptoms.
Metrics
References
Nakano Y, Kanda T. Pathology of the Peripheral Nervous System in Guillain-Barré Syndrome. Brain Nerve 2015;67:1329-39. https://doi.org/10.11477/mf.1416200303
Van Den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014;10:469-82. https://doi.org/10.1038/nrneurol.2014.121
Wijdicks EFM, Klein CJ. Guillain-Barré Syndrome. Mayo Clin Proc 2017;92:467-79. https://doi.org/10.1016/j.mayocp.2016.12.002
Koike H, Chiba A, Katsuno M. Emerging Infection, Vaccination, and Guillain-Barré Syndrome: A Review. Neurol Ther 2021;10:523-37. https://doi.org/10.1007/s40120-021-00261-4
Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barré syndrome. Hum Vaccin Immunother 2018;14:2568-79. https://doi.org/10.1080/21645515.2018.1493415
Berciano J. Axonal pathology in early stages of Guillain-Barré syndrome. Neurologia 2022;37:466-79. https://doi.org/10.1016/j.nrl.2018.06.002
Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet 2021;397:1214-28. https://doi.org/10.1016/S0140-6736(21)00517-1
Lleixà C, Martín-Aguilar L, Pascual-Goñi E, Franco T, Caballero M, de Luna N, et al. Autoantibody screening in Guillain-Barré syndrome. J Neuroinflammation 2021;18:251. https://doi.org/10.1186/s12974-021-02301-0
Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet 2021;397:1214-28. https://doi.org/10.1016/S0140-6736(21)00517-1
Malek E, Salameh J. Guillain-Barre Syndrome. Seminars in Neurology 2019;39:589-95. https://doi.org/10.1055/s-0039-1693005
Marcus R. What Is Guillain-Barré Syndrome? JAMA 2023;329:602. https://doi.org/10.1001/jama.2022.24232
Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2020;1:CD008630. https://doi.org/10.1002/14651858.CD008630.pub5
Ethemoglu O, Calik M. Effect of serum inflammatory markers on the prognosis of adult and pediatric patients with Guillain-Barré syndrome. Neuropsychiatr Dis Treat 2018;14:1255-60. https://doi.org/10.2147/NDT.S162896
Leonhard SE, Bresani-Salvi CC, Lyra Batista JD, Cunha S, Jacobs BC, Brito Ferreira ML, et al. Guillain-Barré syndrome related to Zika virus infection: A systematic review and meta-analysis of the clinical and electrophysiological phenotype. PLOS Neglected Trop Dis 2020;14:e0008264. https://doi.org/10.1371/journal.pntd.0008264
Yadegari S, Nafissi S, Kazemi N. Comparison of electrophysiological findings in axonal and demyelinating Guillain-Barre syndrome. Iran J Neurol 2014;13:138-43. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240930/
Vargas-Cañas ES, Galnares-Olalde JA, León-Velasco F, García-Grimshaw M, Gutiérrez A, López-Hernández JC. Prognostic Implications of Early Albuminocytological Dissociation in Guillain-Barré Syndrome. Can J Neurol Sci 2023;50:745-50. https://doi.org/10.1017/cjn.2022.288
Jahan I, Ahmed R, Ahmed J, Khurshid S, Biswas PP, Upama IJ, et al. Neutrophil-lymphocyte ratio in Guillain-Barré syndrome: A prognostic biomarker of severe disease and mechanical ventilation in Bangladesh. JPNS 2023;28:47-57. https://doi.org/10.1111/jns.12531
Sarejloo S, Khanzadeh S, Hosseini S, Gargari MK, Lucke-Wold B, Mosalamiaghili S, et al. Role of the Neutrophil to Lymphocyte Ratio in Guillain Barré Syndrome: A Systematic Review and Meta-Analysis. Yin G, editor. Mediators Inflamm 2022;2022:1-13. https://doi.org/10.1111/jns.12531
Kalita J, Misra UK, Chaudhary SK, Das M, Mishra A, Ranjan A, et al. Outcome of Guillain–Barré syndrome following intravenous immunoglobulin compared to natural course. Eur J Neurol 2022;29:3071-80. https://doi.org/10.1111/ene.15500
Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 2021;20:275-83. https://doi.org/10.1016/S1474-4422(20)30494-4
Gevorgyan A, Sanossian N, Beydoun SR. Guillain-Barré Syndrome Trend of Hospital Length of Stay, Complication Rate and Mortality Depending from Method of the Treatment: IVIg vs. PLEX (P5.137). Neurology 2017;88(16 Supplement):79758331. https://doi.org/10.1212/WNL.88.16_supplement.P5.137
Ginanneschi F, Giannini F, Sicurelli F, Battisti C, Capoccitti G, Bartalini S, et al. Clinical Features and Outcome of the Guillain–Barre Syndrome: A Single-Center 11-Year Experience. Front Neurol 2022;13:856091. https://doi.org/10.3389/fneur.2022.856091
Bentley SA, Ahmad S, Kobeissy FH, Toklu HZ. Concomitant Guillain–Barré Syndrome and COVID-19: A Meta-Analysis of Cases. Medicina 2022;58:1835. https://doi.org/10.3390/medicina58121835
Fernandez P, Pereira JM, Risso IS, Silva PA, Caroline I, Vieira G, et al. Guillain‐Barre syndrome following COVID‐19 vaccines: A scoping review. Acta Neurol Scan 2021;145:393-8. https://doi.org/10.1111/ane.13575
Lupu VV, Miron I, Cianga AL, Gavrilovici C, Grigore I, David AG, et al. Diagnostic Pitfalls in Guillain–Barré Syndrome: Case Report and Literature Review. Children 2022;9:1969. https://doi.org/10.3390/children9121969
Pimentel V, Luchsinger VW, Carvalho GL, Alcará AM, Esper NB, Marinowic D, et al. Guillain–Barré syndrome associated with COVID-19: A systematic review. Brain Behav Immun Health 2023;28:100578. https://doi.org/10.1016/j.bbih.2022.100578
Yi SW, Lee JH, Hong JM, Choi YC, Park HJ. Incidence, Disability, and Mortality in Patients With Guillain-Barré Syndrome in Korea: A Nationwide Population-Based Study. J Clin Neurol 2022;18:48-58. https://doi.org/10.3988/jcn.2022.18.1.48
Capasso A, Ompad DC, Vieira DL, Wilder-Smith A, Tozan Y. Incidence of Guillain-Barré Syndrome (GBS) in Latin America and the Caribbean before and during the 2015–2016 Zika virus epidemic: A systematic review and meta-analysis. PLOS Neglected Trop Dis 2019;13:e0007622. https://doi.org/10.1371/journal.pntd.0007622
Martín-Aguilar L, Camps-Renom P, Lleixà C, Pascual-Goñi E, Díaz-Manera J, Rojas-García R, et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. J Neurol Neuros Psychiatr 2020;2020:323899. https://doi.org/10.1136/jnnp-2020-323899
Cao Y, Ji S, Chen Y, Zhang X, Ding G, Tang F. Association between autoimmune diseases of the nervous system and schizophrenia: A systematic review and meta-analysis of cohort studies. Compreh Psychiatr 2023;122:152370. https://doi.org/10.1016/j.comppsych.2023.152370
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Pedro Henrique Rocha Zin, Jucélia Jeremias Fortunato
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
Accepted 2024-05-21
Published 2024-07-10
